Clinical uses of GM-CSF, a critical appraisal and update.
about
Trial WatchThe importance of the granulocyte-colony stimulating factor in oncologyFrom bench to bedside: immunotherapy for prostate cancerTrial Watch-Immunostimulation with cytokines in cancer therapyTrial watch: Immunostimulatory cytokines in cancer therapy.Immunotherapy for malignant pleural mesothelioma: current status and future directions.Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells.Classification of current anticancer immunotherapiesGM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravisActivation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.Trial watch: Naked and vectored DNA-based anticancer vaccinesA Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents.Synthesis of granulocyte-macrophage colony-stimulating factor as homogeneous glycoforms and early comparisons with yeast cell-derived material.Neutrophils acquire the capacity for antigen presentation to memory CD4+ T cells in vitro and ex vivo.GM-CSF pathway correction in pulmonary alveolar proteinosis.Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders.Combinatorial drug delivery approaches for immunomodulation.Novel oncolytic viral therapies in patients with thoracic malignancies.Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand?Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer players.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
P2860
Q24618653-961B8883-E73D-4AD0-9E7B-66E5EC2E5BA8Q26770908-F1E7009E-5BDB-4553-A70F-9FB3FDE8D570Q26864390-11CEC245-5A54-45DF-BF2B-66AC4B0DC0E3Q28078725-5E9BC206-6B6C-4D5E-8C0B-5A844C8F21CFQ33880165-06F9C0E3-BEF7-416B-BD00-21F9341B44EEQ33890551-795FBE14-F130-479E-A5FB-B7A5E9ED4ADEQ34183436-2C43006D-25A9-4371-BEC5-7642EFE4FE43Q34931766-E6F95D65-D89A-469E-95AC-A0C1AA11FF3EQ35149637-47EEA7B4-FD5F-4099-8D19-F2FA3F17DDF5Q35603050-8A445525-995E-460A-A5B6-B93CDD86C0D7Q35721147-99AB5E30-E38C-4B44-B6A9-E9DFC6DC4C2FQ35798986-7DFD2A9C-0DBC-4B61-AC27-306FBB33AA06Q35874291-3D888B6A-D1ED-4A42-8DB1-78923D1AB5A7Q37612674-01331F71-50AB-4F04-885E-211F3650FBA4Q37740860-848F653B-1139-4F7E-8379-6FEE2F8DF83BQ37778844-E9220A83-0353-4B56-8D72-B95016471772Q38267711-E7CDCED7-F08E-40ED-9DB9-D402D7B245CFQ38680602-477DED58-C74D-4504-A377-4E60B758AE87Q39067827-CC3FDCAC-1BBE-406E-B263-73BF6F7E98BEQ40806737-9E1398FC-3289-4A38-88F6-1404174129D9Q52665595-F1503206-D475-4F46-BF17-C3738767BE42Q55425154-9BF23CF9-7651-4E2D-A753-A823888E2559Q56892924-C8255D78-DFF9-403D-A89D-F1F7509CE1F2
P2860
Clinical uses of GM-CSF, a critical appraisal and update.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Clinical uses of GM-CSF, a critical appraisal and update.
@en
Clinical uses of GM-CSF, a critical appraisal and update.
@nl
type
label
Clinical uses of GM-CSF, a critical appraisal and update.
@en
Clinical uses of GM-CSF, a critical appraisal and update.
@nl
prefLabel
Clinical uses of GM-CSF, a critical appraisal and update.
@en
Clinical uses of GM-CSF, a critical appraisal and update.
@nl
P2860
P356
P1476
Clinical uses of GM-CSF, a critical appraisal and update.
@en
P2093
Martha Arellano
P2860
P356
10.2147/BTT.S1355
P50
P577
2008-03-01T00:00:00Z